222 related articles for article (PubMed ID: 31015314)
1. Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?
Wong A; Billett A; Milne D
Oncologist; 2019 Nov; 24(11):e1190-e1196. PubMed ID: 31015314
[TBL] [Abstract][Full Text] [Related]
2. Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy.
Levy D; Dhillon HM; Lomax A; Marthick M; McNeil C; Kao S; Lacey J
Support Care Cancer; 2019 May; 27(5):1845-1852. PubMed ID: 30178142
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
Livingstone A; Dempsey K; Stockler MR; Howard K; Long GV; Carlino MS; Menzies AM; Morton RL
BMC Cancer; 2021 Sep; 21(1):1014. PubMed ID: 34507552
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Experiences of People Treated With Immunotherapies for Advanced Melanoma and Those Caring for Them: "Real-World" Data.
Milne D; Hyatt A; Billett A; Gough K; Krishnasamy M
Cancer Nurs; 2020; 43(2):E97-E104. PubMed ID: 30801266
[TBL] [Abstract][Full Text] [Related]
5. Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Wang M; Chen C; Jemielita T; Anderson J; Li XN; Hu C; Kang SP; Ibrahim N; Ebbinghaus S
J Immunother Cancer; 2019 Feb; 7(1):39. PubMed ID: 30736858
[TBL] [Abstract][Full Text] [Related]
6. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
7. Approaches to decision-making among late-stage melanoma patients: a multifactorial investigation.
Garrett SB; Abramson CM; Rendle KA; Dohan D
Support Care Cancer; 2019 Mar; 27(3):1059-1070. PubMed ID: 30136025
[TBL] [Abstract][Full Text] [Related]
8. Preferences for Immunotherapy in Melanoma: A Systematic Review.
Livingstone A; Agarwal A; Stockler MR; Menzies AM; Howard K; Morton RL
Ann Surg Oncol; 2020 Feb; 27(2):571-584. PubMed ID: 31664622
[TBL] [Abstract][Full Text] [Related]
9. The Option Value of Innovative Treatments for Metastatic Melanoma.
Thornton Snider J; Seabury S; Tebeka MG; Wu Y; Batt K
Forum Health Econ Policy; 2018 Jun; 21(1):. PubMed ID: 30210050
[TBL] [Abstract][Full Text] [Related]
10. What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists.
Rocque GB; Rasool A; Williams BR; Wallace AS; Niranjan SJ; Halilova KI; Turkman YE; Ingram SA; Williams CP; Forero-Torres A; Smith T; Bhatia S; Knight SJ
Oncologist; 2019 Oct; 24(10):1313-1321. PubMed ID: 30872466
[TBL] [Abstract][Full Text] [Related]
11. Balancing Hope and Risk Among Adolescent and Young Adult Cancer Patients with Late-Stage Cancer: A Qualitative Interview Study.
Figueroa Gray M; Ludman EJ; Beatty T; Rosenberg AR; Wernli KJ
J Adolesc Young Adult Oncol; 2018 Dec; 7(6):673-680. PubMed ID: 30096254
[TBL] [Abstract][Full Text] [Related]
12. Patient Decision-Making About Emergency and Planned Stoma Surgery for IBD: A Qualitative Exploration of Patient and Clinician Perspectives.
Dibley L; Czuber-Dochan W; Wade T; Duncan J; Burch J; Warusavitarne J; Norton C; Artom M; O'Sullivan L; Verjee A; Cann D;
Inflamm Bowel Dis; 2018 Jan; 24(2):235-246. PubMed ID: 29361098
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
14. Family involvement in cancer treatment decision-making: A qualitative study of patient, family, and clinician attitudes and experiences.
Laidsaar-Powell R; Butow P; Bu S; Charles C; Gafni A; Fisher A; Juraskova I
Patient Educ Couns; 2016 Jul; 99(7):1146-1155. PubMed ID: 26873544
[TBL] [Abstract][Full Text] [Related]
15. From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
Kamminga NCW; van der Veldt AAM; Wakkee M; van den Berge FR; van der Beek LAA; Joosen MCW; Joosse A; de Joode K; Nijsten TEC; Lugtenberg M
BMC Cancer; 2024 May; 24(1):662. PubMed ID: 38816701
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada.
Cheung WY; White MK; Bayliss MS; Stroupe A; Lovley A; King-Kallimanis BL; Lasch K
Support Care Cancer; 2019 Jan; 27(1):219-227. PubMed ID: 29934684
[TBL] [Abstract][Full Text] [Related]
17. The views and experiences of older people with conservatively managed renal failure: a qualitative study of communication, information and decision-making.
Selman LE; Bristowe K; Higginson IJ; Murtagh FEM
BMC Nephrol; 2019 Feb; 20(1):38. PubMed ID: 30717686
[TBL] [Abstract][Full Text] [Related]
18. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
McDermott D; Lebbé C; Hodi FS; Maio M; Weber JS; Wolchok JD; Thompson JA; Balch CM
Cancer Treat Rev; 2014 Oct; 40(9):1056-64. PubMed ID: 25060490
[TBL] [Abstract][Full Text] [Related]
19. Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy.
McMullen S; Hess LM; Kim ES; Levy B; Mohamed M; Waterhouse D; Wozniak A; Goring S; Müller K; Muehlenbein C; Aggarwal H; Zhu Y; Oton AB; Ersek JL; Winfree KB
Patient; 2019 Apr; 12(2):223-233. PubMed ID: 30128728
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
Tiu C; Wong A; Herschtal A; Mileshkin L
Asia Pac J Clin Oncol; 2018 Aug; 14(4):337-342. PubMed ID: 29498208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
